Effects of PTTG down-regulation on proliferation and metastasis of the SCL-1 cutaneous squamous cell carcinoma cell line

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6245-6248

  Xia, Yong Hua ^a   Li, Min ^a   Fu, Dan Dan ^a   Xu, Su Ling ^a   Li, Zhan Guo ^a   Liu, Dong ^a   Tian, Zhong Wei ^a  

^a XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Cutaneous squamous cell carcinoma; Metast; Pituitary tumor; Proliferation; Transforming gene

Indexed keywords

GELATINASE A; GELATINASE B; PITUITARY TUMOR-TRANSFORMING PROTEIN 1, HUMAN; SECURIN;

CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; GENETICS; HUMAN; METASTASIS; PATHOLOGY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM METASTASIS; SECURIN; SKIN NEOPLASMS;

EID: 84892461850     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6245     Document Type: Article

References (28)

1. Akino K, Akita S, Mizuguchi T, et al (2005). A novel molecular marker of pituitary tumor transforming gene involves in a rat liver regeneration. J Surg Res, 129, 142-6.
2. Bhave SL, Teknos TNPan Q (2011). Molecular parameters of head and neck cancer metastasis. Crit Rev Eukaryot Gene Expr, 21, 143.
3. Bogusiewicz M, Stryjecka-Zimmer M, Szymanski M, et al (2003). Activity of matrix metalloproteinases-2 and -9 in advanced laryngeal cancer. Otolaryngol Head Neck Surg, 2003, 132-6.
4. Chen G, Li J, Li F, et al (2004). Inhibitory effects of anti-sense pttg on malignant phenotype of human ovarian carcinoma cell line sk-ov-3. J Huazhong Univ Sci Technolog Med Sci, 24, 369-72.(In Chinease)
5. Chollet A, Hohl D, Perrier P (2012). Risk of cutaneous squamous cell carcinomas: The role of clinical and pathological reports]. Rev Med Suisse, 8, 743.
6. Coussens LM, Tinkle CL, Hanahan D, et al (2000). Mmp-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103, 481-90.
7. Fang J, Shing Y, Wiederschain D, et al (2000). Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Ncad Sci USA, 97, 3884-9.
8. Franchi A, Santucci M, Masini E, et al (2002). Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer, 95, 1902-10.
9. Gelse K, Pöschl E, Aigner T (2003). Collagens-structure, function, and biosynthesis. Adv Drug Deliv Rev, 55, 1531-46.
10. Geneva, Switzerland: World Health Organization. Too Much Fun in the Sun Dangerous; Press Release WHO/40; 3 August 1999. http://www.who.int/inf-pr-1999/en/pr99-40.html
11. Goh RY, Bova R, Fogarty GB (2012). Cutaneous squamous cell carcinoma metastatic to parotid-analysis of prognostic factors and treatment outcome. World J Surg Oncol, 10, 1-5.
12. Itoh Y, Nagase H (2002). Matrix metalloproteinases in cancer. Essays Biochem, 38, 21-36.
13. Jung CR, Yoo J, Jang YJ, et al (2006). Adenovirus-mediated transfer of sirna against pttg1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology, 43, 1042-52.
14. Kakar SS, Malik MT (2006). Suppression of lung cancer with sirna targeting pttg. Int J Oncol, 29, 387.
15. Kessenbrock K, Plaks V, Werb Z (2010). Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell, 141, 52-67.
16. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25, 402-8.
17. London CA, Sekhon HS, Arora V, et al (2003). A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther, 10, 823-32.
18. Moore BA, Weber RS, Prieto V, et al (2005). Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope, 115, 1561-7.
19. Mourouzis C, Boynton A, Grant J, et al (2009). Cutaneous head and neck sccs and risk of nodal metastasis-uk experience. J Craniomaxillofac Surg, 37, 443-7.
20. Ondruschka C, Buhtz P, Motsch C, et al (2002). Prognostic value of MMP-2,-9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res Pract, 198, 509-15.
21. Patel V, Ramesh A, TraicoffJL, et al (2005). Profiling egfr activity in head and neck squamous cell carcinoma by using a novel layered membrane western blot technology. Oral Oncol, 41, 503-8.
22. Pei L, Melmed S (1997). Isolation and characterization of a pituitary tumor-transforming gene (pttg). Mol Endocrinol, 11, 433-41.
23. Roy R, Yang J, Moses MA (2009). Matrix metalloproteinases as novel biomarker s and potential therapeutic targets in human cancer. J Clin Oncol, 27, 5287-97.
24. Shibata Y, Haruki N, Kuwabara Y, et al (2002). Expression of pttg (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol, 32, 233-7.
25. Solbach C, Roller M, Fellbaum C, et al (2004). PTTG mRNA expression in primary breast cancer: A prognostic marker for lymph node invasion and tumor recurrence. Breast, 13, 80-1.
26. Urba W, Washington C, Nadiminti H (2012). Cancer of the Skin. In: Harrison's Principles of Internal Medicine (18th Edition) (Longo DL, Hause SL, Jameson JL and Loscalzo, eds.). McGraw-Hill Medical Publishing Division, New York.
27. Woodhouse EC, Chuaqui RF, Liotta LA (1997). General mechanisms of metastasis. Cancer, 80, 1529-37.
28. Zhang X, Horwitz GA, Heaney AP, et al (1999). Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab, 84, 761-7.